BCIQ Profiles

Company Profile ReportTarget Profile Report
0716 QT
BioCentury & Getty Images

Regulation

July 16 Quick Takes: ROCK brings Kadmon first win at FDA; plus Merck, Moderna, Alexion, HIFs and more  

Jul 17, 2021 | 12:54 AM GMT

The first approval for Kadmon Holdings Inc. (NYSE:KDMN) — Rezurock belumosudil for third-line chronic graft-versus-host disease (cGVHD) — marks FDA’s first approval of a small molecule ROCK2 inhibitor. The approval, completed under Project Orbis and FDA’s Real-Time Oncology Review pilot program, came six weeks ahead

Read the full 705 word article

How to gain access

Continue reading with a
two-week free trial.